US Pharma MarketingThe post Lilly’s JAK2 inhibitor from $2.3bn acquisition shows early promise appeared first on Clinical Trials Arena.
Lilly’s JAK2 inhibitor from $2.3bn acquisition shows early promise
Lilly presented Phase I data from the type II JAK inhibitor, showing good efficacy and safety. Lilly presented Phase I data from the type II JAK inhibitor, showing good efficacy and safety. Lilly acquired Ajax Therapeutics in April 2026. Credit: Tada Images / Shutterstock.com Eli Lilly’s type II JAK2 inhibitor, which it acquired through the $2.3bn acquisition of Ajax Therapeutics earlier this year, has shown an encouraging safety profile and promising clinical activity in a Phase I trial. In the AJX-101 study (NCT06343805), AJ1-11095, a once-daily oral medication, was investigated in patients with myelofibrosis who did not respond to previous…
Lilly presented Phase I data from the type II JAK inhibitor, showing good efficacy and safety.
Source: Clinical Trials Arena